Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women.

Unlabelled: FGF-23 is a novel regulator of phosphate metabolism. We studied the regulation of FGF-23 by dietary phosphate in 66 men and women using two assays. Dietary phosphate restriction decreased FGF-23 and loading increased FGF-23 significantly.

Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men.

Context: We have previously demonstrated that alendronate reduces the ability of teriparatide to increase bone mineral density (BMD) in osteoporotic men. The underlying basis for this observation is poorly understood.

Objective: The primary aim of this study was to determine whether teriparatide increases osteoblast activity when the ability of teriparatide to increase osteoclast activity is suppressed by alendronate.

Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.

Objective: A 1-yr extension of the Fosamax Actonel Comparison Trial was completed to compare changes in bone mineral density (BMD), bone turnover, and upper gastrointestinal tolerability over 2 yr of treatment.

Design: This was a randomized, double-blind extension conducted at 72 U.S.